| scholarly article | Q13442814 |
| P50 | author | Mitchell S. Stark | Q54836800 |
| Vanessa F Bonazzi | Q55303023 | ||
| Sandra Pavey | Q56495714 | ||
| Barry S Taylor | Q88249464 | ||
| Christine A Pratilas | Q102380741 | ||
| P2093 | author name string | Neal Rosen | |
| Paul D Smith | |||
| Richard S Finn | |||
| David B Solit | |||
| Mark Cockerill | |||
| Nicholas K Hayward | |||
| Helen Brown | |||
| Feng Xing | |||
| Judy Dering | |||
| Tim French | |||
| Andrew Cassidy | |||
| Chris Harbron | |||
| Garry Beran | |||
| Jonathan R Dry | |||
| Darren Hodgson | |||
| Alexander Graham | |||
| Christine Chresta | |||
| Rose McCormack | |||
| Sarah Runswick | |||
| Sugandha Ravishankar | |||
| Gillian Ellison | |||
| Leisl Packer | |||
| Natalie Byrne | |||
| Carolyn Haggerty | |||
| P2860 | cites work | Clusterin inhibits apoptosis by interacting with activated Bax | Q24316499 |
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| ONCOMINE: a cancer microarray database and integrated data-mining platform | Q28255103 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery | Q30443764 | ||
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 | ||
| TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation | Q33348778 | ||
| Effects of threshold choice on biological conclusions reached during analysis of gene expression by DNA microarrays | Q33852330 | ||
| RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects | Q34081008 | ||
| Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines | Q34253092 | ||
| Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer | Q34596148 | ||
| Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. | Q34603719 | ||
| The role of companion diagnostics in the development and use of mutation-targeted cancer therapies | Q36561648 | ||
| Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting | Q36709828 | ||
| Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development | Q36713660 | ||
| Melanocyte receptors: clinical implications and therapeutic relevance. | Q36954814 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Genetic predictors of MEK dependence in non-small cell lung cancer | Q37113682 | ||
| Extracellular signal-regulated kinase mitogen-activated protein kinase signaling initiates a dynamic interplay between sumoylation and ubiquitination to regulate the activity of the transcriptional activator PEA3. | Q37192018 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation | Q37401349 | ||
| Biomarkers in oncology drug development | Q37453841 | ||
| A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis | Q38289998 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer | Q39860040 | ||
| Tribbles-2 is a novel regulator of inflammatory activation of monocytes | Q39924906 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. | Q40105282 | ||
| Confirmation of a BRAF mutation-associated gene expression signature in melanoma. | Q40129786 | ||
| Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection | Q40164471 | ||
| Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro | Q40176252 | ||
| Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors | Q40296280 | ||
| Microarray expression profiling in melanoma reveals a BRAF mutation signature. | Q40572664 | ||
| Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation | Q41822622 | ||
| Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | Q46868532 | ||
| Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion. | Q53542029 | ||
| Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. | Q55043619 | ||
| The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades | Q71536070 | ||
| BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 | ||
| Take your "M" time | Q81304176 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2264-2273 | |
| P577 | publication date | 2010-03-09 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | |
| P478 | volume | 70 |
| Q36714160 | A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. |
| Q41159551 | A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction |
| Q47099062 | A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer |
| Q28540936 | A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines |
| Q37017721 | A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. |
| Q31081853 | A new molecular signature method for prediction of driver cancer pathways from transcriptional data |
| Q56985652 | A quantile regression forest based method to predict drug response and assess prediction reliability |
| Q31056926 | A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. |
| Q55259943 | A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. |
| Q39375855 | Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. |
| Q38338335 | Activation and involvement of Ral GTPases in colorectal cancer |
| Q37529969 | Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells |
| Q36166893 | Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer |
| Q53264472 | Advances in the preclinical testing of cancer therapeutic hypotheses. |
| Q30409158 | Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity |
| Q24601008 | Analysis of the genome to personalize therapy for melanoma |
| Q42437883 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells |
| Q37702515 | BRAF and beyond: Tailoring strategies for the individual melanoma patient |
| Q41071955 | BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis |
| Q42478581 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells |
| Q55335270 | Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. |
| Q52707917 | COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. |
| Q38913787 | Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma |
| Q50541243 | Consistency in large pharmacogenomic studies. |
| Q38904777 | Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. |
| Q47145152 | Correlation between MEK signature and Ras gene alteration in advanced gastric cancer |
| Q27316921 | Cortactin Phosphorylated by ERK1/2 Localizes to Sites of Dynamic Actin Regulation and Is Required for Carcinoma Lamellipodia Persistence |
| Q33677196 | Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease |
| Q39122119 | DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype |
| Q33861173 | Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma |
| Q24294914 | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors |
| Q57174616 | Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients |
| Q89735512 | Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD |
| Q34289063 | Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling |
| Q91992324 | Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma |
| Q38877096 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. |
| Q37933855 | EGFR-targeted therapy |
| Q46343415 | ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues |
| Q36900522 | Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors |
| Q35079398 | Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia |
| Q41697013 | Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib |
| Q46124941 | Expanding targeted therapy to NRAS-mutated melanoma |
| Q52580320 | Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease. |
| Q28551145 | HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B |
| Q36268787 | High-dimensional omics data analysis using a variable screening protocol with prior knowledge integration (SKI) |
| Q34129528 | Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines |
| Q37596249 | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. |
| Q33957184 | Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. |
| Q34272199 | Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance |
| Q38402255 | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells |
| Q39396267 | Inhibition of metadherin sensitizes breast cancer cells to AZD6244. |
| Q34797680 | Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery |
| Q34273541 | Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells |
| Q38390027 | KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach |
| Q42778262 | KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer. |
| Q38728970 | Looking beyond the cancer cell for effective drug combinations |
| Q38514737 | Low-grade serous carcinoma: molecular features and contemporary treatment strategies |
| Q38109432 | Low-grade serous carcinoma: new concepts and emerging therapies. |
| Q93018169 | MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells |
| Q38744494 | MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling |
| Q37161421 | MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines |
| Q92531455 | MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q38591835 | MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road |
| Q36976683 | MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands |
| Q64071499 | MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification whereas KRAS amplification promotes EMT-chemoresistance |
| Q52607333 | Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. |
| Q89303329 | Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine |
| Q92266361 | Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival |
| Q53205249 | Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. |
| Q35023456 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers |
| Q90270016 | National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer |
| Q34161395 | New driver mutations in non-small-cell lung cancer |
| Q37183820 | Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma |
| Q38084846 | PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types |
| Q55344912 | PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. |
| Q91896914 | PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC |
| Q33793611 | Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour |
| Q88766400 | Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer |
| Q34633455 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma |
| Q39355884 | Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. |
| Q37421431 | Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. |
| Q39367867 | Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. |
| Q38686612 | Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells |
| Q37047974 | RAF265 inhibits the growth of advanced human melanoma tumors |
| Q39140763 | Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer |
| Q90250029 | Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q47432675 | SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer |
| Q36083385 | STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. |
| Q39537501 | Simultaneous measurement of ERα, HER2, and phosphoERK1/2 in breast cancer cell lines by flow cytometry |
| Q35610049 | Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. |
| Q34526671 | Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
| Q29547695 | Systematic identification of genomic markers of drug sensitivity in cancer cells |
| Q35822194 | Targeted agents for the treatment of metastatic melanoma |
| Q38060508 | Targeting MEK for the treatment of non-small-cell lung cancer |
| Q38682370 | Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications |
| Q51609396 | Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. |
| Q29547693 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity |
| Q54977373 | The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. |
| Q38212717 | The clinical development of MEK inhibitors |
| Q26747403 | The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers |
| Q39383689 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q37514034 | To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients |
| Q38466630 | Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. |
| Q47648793 | lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. |
| Q35621787 | β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas |
Search more.